Area of research
Pulmonary and Respiratory Medicine · Gastroenterology
Research interest
Research interests include Medicine, Internal medicine, Imatinib, Sunitinib, GiST, and Regorafenib.
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Recent Advances in Desmoid Tumor Therapy
Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
New frontiers in the medical management of gastrointestinal stromal tumours
Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients
Unexpected benefit from an ‘old’ metronomic chemotherapy regimen in advanced chordoma
Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.
Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients.
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin
Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas
Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.
Rechallenge in GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey
BMI as a risk factor for toxicities in patients with advanced soft tissue sarcoma treated with trabectedin.
Drug-induced hepatotoxicity in cancer patients - implication for treatment
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience
Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study
Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey
Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.
Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to discontinue the treatment?